



Oncoendocrinology SIG 2024-2025 Steering Group Roster

Co-Chairs



Yee-Ming Melody Cheung, MD, PhD
*Northwell Health
Boston, MA, USA*

Dr. Melody Cheung is an attending endocrinologist and the Director of CME for the Division of Endocrinology at Northwell Health.

She graduated medical school from Monash University in Australia and completed Internal Medicine residency and Endocrinology Fellowship at the University of Melbourne in Australia. Subsequently, she undertook a clinical research fellowship in onco-endocrinology at the Brigham and Women's Hospital and Dana-Farber Cancer Institute, affiliates of Harvard Medical School in Boston, MA. During this time, she completed a PhD investigating the cardiometabolic effects of breast cancer therapies. Her clinical practice focuses on providing care to oncology patients with a variety of endocrine conditions that occur as a direct consequence of their cancer, or cancer treatment.



Emily Gallagher, MD, PhD
*Ichan School of Medicine at Mount Sinai
New York, NY, USA*

Dr. Gallagher is an Associate Professor of Medicine, member of the Tish Cancer Institute, and Director of the American Board of Internal Medicine Research Pathway for residents at the Icahn School of Medicine at Mount Sinai. She is an NIH-funded physician-scientist whose translational research involves understanding the mechanisms through which dyslipidemia and hyperinsulinemia impact cancer progression, as well as the metabolic and endocrine effects of novel cancer therapies. In her onco-endocrinology clinical practice she treats metabolic and endocrine disorders that occur in individuals with cancer, or as a result of cancer treatment.

Immediate Past Chair



Afreen Shariff, MD
Duke University
Durham, NC

Dr. Shariff is an Associate Professor of Medicine, Director of the Duke Endo Oncology Program and the Associate Director, Cancer Therapy Toxicity Program at the Center for Cancer Immunotherapy at the Duke Cancer Institute. She is also the host and producer for the irAE focused medical podcast series, Checkpoint NOW, the co-founder for Citrus Oncology and the co-lead for the international Alliance for Support and Prevention of immune related Events (ASPIrE).

Dr. Shariff leads patient centric programs targeted at improving access and reducing healthcare utilization related to endocrine emergencies in cancer patients through the effective use of electronic consultative services and ML/AI assisted clinical decision tools that provide patient specific prediction of immune related adverse events.

Dr. Shariff is passionate about enhancing education and improving science and clinical practice through collaboration. She is the founding Co-chair of the Oncoendocrinology SIG (2022-2024) and continues to support the mission as part of the steering committee.

Steering Group Members

Tugce Akcan, MD
Stanford University
Stanford, CA, USA

Melissa Lechner, MD, PhD
University of California Los Angeles
Los Angeles, CA, USA

Cherie Chiang, MBBS, FRACP, FRCPA
Royal Melbourne Hospital
Melbourne, Australia

Christopher Muir, MBBS
Holdsworth House Medical Practice
Queensland, Australia

Diana Dimayuga, MD
Brigham and Women's Hospital
Boston, MA, USA

Zoe Quandt, MD, MS
University of California San Francisco
San Francisco, CA, USA

Ruti Karov, MD
Sourasky Medical Center
Tel Aviv, Israel

Ling Zhu, MB, BChir, FRCP
Singapore General Hospital
Singapore

Anupam Kotwal, MD
University of Nebraska
Omaha, NE, USA